A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients
About this study
Current agents administered in therapeutic regimens of prostate cancer employ different mechanisms to eliminate neoplastic cells by inducing substantial apoptosis and causing tumor regression. Treatment with neoadjuvant chemotherapy before radical prostatectomy may better control the tumor before it has the chance to convert into the disease of castration-resistant prostate cancer (CRPC), which is finally refractory to most modalities of clinical intervention with a clinically lethal nature.
- Condition
- Prostate Cancer Patients
- Tested
- Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Who can join
- Age
- 40 to 75 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
Inclusion 9
- Minimum age: 40 years
- Maximum age: 75 years
- Eligible sex: Male
- Study condition: Prostate Cancer Patients
- 40 ≤ age ≤ 75 years with histologically proven PCa
- no severe major organ dysfunction
- WHO performance status of 0 or 1
- no prior cancer chemotherapy
- A Clinical Stage ≥ T2c (T2c, N0, M0) of prostate cancer but ideally without diagnosed distant metastasis (according to the 2016 American Joint Committee on Cancer (AJCC) definition of TNM staging system, Staging Manual, Eighth Edition) as determined by a preoperative evaluation that included a pleural computed tomography (CT) scan.
Exclusion 5
- age ≥ 76
- severe major organ dysfunction
- WHO performance status of \>1
- prior cancer chemotherapy
- Stage IV.
Where
2 sites, 2 recruiting
Qilu Hospital of Shandong University
Qingdao, Shandong, China
Zhongshan Hospital
Shanghai, China
Contact
-
Yu Sun, Ph.D
86-21-54923302 sunyu@sibs.ac.cn
-
Weijun Ma, Ph.D
86-21-54923268 wjma@sibs.ac.cn
Potential match only. Final eligibility is determined by the study team.